Skip to content

Elucidation of the Effects of Growth Hormone (GH) Deficiency and GH Replacement on Clot and Platelet

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02049671
Enrollment
150
Registered
2014-01-30
Start date
2013-06-01
Completion date
2020-07-30
Last updated
2019-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypopituitary Adults

Brief summary

Large population studies of hypopituitary adults (patients with pituitary gland failure) on conventional hormone replacement, but not growth hormone, have an approximate two fold increase in death rate (mortality). The vast majority of this excess mortality relates to vascular disease. While it is possible that overreplacement with steroids, underreplacement with thyroid hormones and sex hormone deficiency contribute, there are increasing data to support a role for GH in the cause of the excess vascular risk. Although a number of surrogates of vascular risk are described in patients with GH deficiency (GHD), how these translate mechanistically into atherothrombotic (blockage of the arteries) disease has not been fully elucidated. This proposed study will analyse both traditional (body composition, serum lipids, handling of sugars)and more complex markers (inflammation, procoagulation, fibrinolysis) of vascular risk/disease. In addition the study will examine 24hr blood pressure, arterial wall thickness, clot structure and function, as well as platelet action. Measurements will be performed at baseline and will be reassessed after patients have been on a stable dose of GH replacement for at least three months. The results of the study will characterise risk factors for vascular disease, and take this a step further to elucidate how these changes translate mechanistically in to vascular damage.

Interventions

Sponsors

The Leeds Teaching Hospitals NHS Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to 90 Years

Inclusion criteria

* Able to give written consent * Adults with confirmed GHD (Insulin stimulation test \<3ug/L) * Other hormone replacement therapy stable for at least three months

Exclusion criteria

* active malignancy * an acute vascular event within three months of the study * any therapy other than hormone replacement * serum creatinine \>120 micromol/l * abnormal LFTs (ALT\>3 fold upper limit of normal)

Design outcomes

Primary

MeasureTime frame
Turbidity analysis.up to 3 years

Countries

United Kingdom

Contacts

Primary ContactRobert Murray, MB;BS, BSc, MD, FRCP
robert.murray@leedsth.nhs.uk01132064578

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026